2000px-bristol-myers_squibb_logo

The microsite is supported by Bristol Myers Squibb.

Highlights

Professional article
View Post

On the downside: throat and liver

In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in each of the different treatment groups. The adverse drug reactions most commonly observed during ozanimod therapy were nasopharyngitis, upper respiratory tract infections, urinary tract infections, elevated alanine aminotransferase and γGT levels, hypertension, and headache…. Dieser Inhalt ist nur für registrierte Benutzer zugänglich () Einloggen Jetzt registrieren
View Post

Selectivity as a distinguishing feature

Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment with S1P receptor modulators. However, the pivotal studies of ozanimod, as well as other data since their completion, suggest a comparatively favorable safety profile [1–3]…. Dieser Inhalt ist nur für registrierte Benutzer zugänglich () Einloggen Jetzt registrieren
View Post

Multiple levels of effectiveness

The two completed phase III studies SUNBEAM [1] and RADIANCE [2] were able to demonstrate the efficacy of the new active substance in the area of other – radiological and clinical – endpoints in addition to a reduction in relapse frequency through therapy with ozanimod. For the first time in MS research, a slowing of brain volume decline was observed in the cortical gray matter and thalamus…. Dieser Inhalt ist nur für registrierte Benutzer zugänglich () Einloggen Jetzt registrieren
View Post

A new player in MS therapy

With the recently approved ozanimod, another potent compound for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated good efficacy and a safety profile comparable to interferon β1a in two randomized multicenter phase 3 trials with a total of over 2600 participants [1,2]. A large follow-up study that included nearly 85% of patients continues to provide consistent results [3]…. Dieser Inhalt ist nur für registrierte Benutzer zugänglich () Einloggen Jetzt registrieren
View Post

A new player in MS therapy

With the recently approved ozanimod, another highly potent agent for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated high efficacy and a safety profile comparable to interferon β1a in two randomized multicenter phase 3 trials with a total of over 2600 participants. A large follow-up study, which included nearly 85% of patients, continues to yield promising results…. Dieser Inhalt ist nur für registrierte Benutzer zugänglich () Einloggen Jetzt registrieren